Founded in Chicago, Illinois, in 2017, Cardio Diagnostics Holdings, Inc. specializes in the creation and market introduction of clinical tests. These diagnostic tools leverage epigenetics to assess cardiovascular disease risk. Among its offerings is Epi+Gen CHD, a test designed to predict the risk of symptomatic coronary heart disease over a three-year timeframe.